Claims
- 1-42. (Canceled)
- 43. A substantially purified scFv antibody comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2445.
- 44. An antibody or antigen binding portion thereof which immunospecifically binds to SEQ ID NO:3, wherein the antibody or antigen binding portion thereof comprises:
a) a variable heavy (VH) complementary determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:67 or an amino acid sequence of a VH CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2445; b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:68 or an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2445. c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:69 or an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2445. d) a variable light (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:70 or an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2445. e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:71 or an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2445; and f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:72 or an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2445.
- 45. The antibody of claim 44, wherein the antibody is a monoclonal antibody.
- 46. The antibody of claim 44, wherein the antibody is a human antibody.
- 47. The antibody of claim 44, wherein the antibody is a humanized antibody.
- 48. The antibody of claim 44, wherein the antibody is a Fab fragment.
- 49. The antibody of claim 44, wherein the antibody is a F(ab′)2 fragment.
- 50. The antibody of claim 44, wherein the antibody is an scFv.
- 51. The antibody of claim 44, wherein the antibody is conjugated to a therapeutic or drug moiety.
- 52. The antibody of claim 51, wherein the therapeutic or drug moiety is selected from the group consisting of a cytotoxin, a therapeutic agent or a radioactive metal ion.
- 53. The antibody of claim 44, wherein the antibody is conjugated to a detectable substance.
- 54. The antibody of claim 53, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.
- 55. A kit comprising an antibody or fragment thereof as in claim 44 and instructions for use.
- 56. A kit comprising an antibody or fragment thereof as in claim 53 and instructions for use.
- 57. A pharmaceutical composition comprising an antibody of claim 51 and a pharmaceutically acceptable carrier.
- 58. A pharmaceutical composition comprising an antibody of claim 44 and a pharmaceutically acceptable carrier.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/610,118, filed Jun. 30, 2000, which is a continuation-in-part of U.S. application Ser. No. 09/503,387, filed Feb. 14, 2000, which is a continuation-in-part of U.S. application Ser. No. 09/454,824, filed Dec. 6, 1999, which is a continuation-in-part of U.S. application Ser. No. 09/345,068, filed Jun. 30, 1999, the entire contents of each of which is incorporated herein by reference its entirety.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09829495 |
Apr 2001 |
US |
Child |
10850034 |
May 2004 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
09610118 |
Jun 2000 |
US |
Child |
09829495 |
Apr 2001 |
US |
Parent |
09503387 |
Feb 2000 |
US |
Child |
09610118 |
Jun 2000 |
US |
Parent |
09454824 |
Dec 1999 |
US |
Child |
09503387 |
Feb 2000 |
US |
Parent |
09345468 |
Jun 1999 |
US |
Child |
09454824 |
Dec 1999 |
US |